

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**



1/32

ACA Activity Effect of Serum vs Fish Gelatin




FIG. 1



2/32

Immunoreactivity of ACA 6501-5A12 Peptide




FIG. 2



3/32

Immunoreactivity of ACA-6626 with Solid Phase Peptides





FIG. 3



Serum Crossreactivity of ACA 6501-5A12 Peptide





FIG. 4



5/32

Serum Crossreactivity of ACA 6626-4D3 Peptide





FIG. 5



6/32

ACA ELISA of Serum 6501



CALCULATION FOR GPL UNITS IN SERUM
6501: 1600dil./50 dil. x 70 GPL= 2240 GPL

FIG. 6B

O.D. 550 nm vs. Std. GPL UNITS





FIG. 6A



7/32

ACA ELISA of Purified Ab fr. Serum 6501



From the graph purified 6501 Ab had 70.1GPL in 0.5 ug / ml
or 140.2GPL in 1 ug / ml

FIG. 7



8/32

2nd. ROUND 3rd. ROUND 4th. ROUND 5th. ROUND C1C2




FIG. 8



9/32

α




FIG. 9



10/32





FIG. 10




11/32

Inhibition of (3B10)4/6501 Derived by 6501
Derived Peptide Monomer with 400 Diluted
Ser.6501



µg PEPTIDE / WELL

FIG. 11



12/32

**Inhibition of Cdl-2.3% Hu Ser.(no IgG) by
Modified Peptides 3G3 with 400x Diluted
Serum 6501**





FIG. 12



13/32

Inhibition of (3B10)4/6501 Derived by Truncated or Non-Truncated 3B10 with 400 Diluted Serum 6501




FIG. 13



14/32

Inhibition of (3B10)4/6501 Derived by Alpha MeP 3B10
Monomer with 400 Diluted Serum 6501




FIG. 14



15/32

Cross reactivity of peptide LJP 688 with aff-ACA

Cardiolipin/ β 2-GPI-coated plates




FIG. 15



16/32

LJP 685-MTU-DABA-PEG (COMPOUND 36)






FIG. 16



17/32

LJP 685-ATU-MTU-AHAB-TEG (COMPOUND 35)



CONCENTRATION OF TOLERAGEN IN DISH.
Treatment groups.

FIG. 17



18/32




FIG. 18



19/32





FIG. 19



20/32

Amino or other positively charged group



$$D(1,2) = 22^\circ$$

Gem-dimethyl or other small hydrophobic group




FIG. 20A





FIG. 20B



21/32

Inhibition of β_2 GP-1 by 6501-Derived Peptides with 350x Diluted Serum 6501




FIG. 21



22/32

**6701 Titration of CB2*-F:
(FITC)-GPCILLARDRCG-CO₂-**




FIG. 22



23/32

**6501 Titration of CB2*-F:
(FITC)-GPCILLARDRCG-CO₂⁻**




FIG. 23



24/32

**6501 Titration of CB2*-F:
(FITC)-GPCILLARDRCG-CO₂⁻**




FIG. 24



25/32

**Displacement of CB2*-F from
6701 using 1.04 eq. of CB2*:
GPCILLARDRCG-CO₂⁻**




FIG. 25



26/32

**CB2* Titration of CB2*-F/6701:
CB2*: GPCILLARDRCG-CO₂⁻**




FIG. 26



27/32

**3B10 Titration of CB2*-F/6701:
3B10: AGPCLLLAPDRCPG-CO₂⁻**





FIG. 27



28/32




FIG. 28



30/32





FIG. 30



31/32





FIG. 31



32/32




FIG. 32



Creation date: 06-03-2004
Indexing Officer: NKING - NICOLE KING
Team: OIPEBackFileIndexing
Dossier: 10044844

Legal Date: 11-14-2003

No.	Doccode	Number of pages
1	CTRS	7

Total number of pages: 7

Remarks:

Order of re-scan issued on